2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2928

Hypomethylation of an Intragenic Alternative Promoter Contributes to Impaired Treg Function in Rheumatoid Arthritis By Transcriptional Interference with Expression of the Treg-Specific Protein, Glycoprotein a Repetitions Predominant (GARP)

T Cell Biology and Targets in Autoimmune Disease - Poster Session II

9:00AM-11:00AM: Abstract Number: 2563

Hypoxia Induce Slug Expression Via JAK/STAT3 Pathway in Rheumatoid Arthritis Fibroblast-like Synoviocytes

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III

9:00AM-11:00AM: Abstract Number: 2696

Identification of a Potential Commensal Immunologic Target in Enthesitis-Related Arthritis

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

9:00AM-11:00AM: Abstract Number: 2427

Identification of Biomarkers Using Tear Proteomics in Children with Chronic Anterior Uveitis

Pediatric Rheumatology – Pathogenesis and Genetics - Poster

9:00AM-11:00AM: Abstract Number: 2121

Identification of microRNA-181a-5p and microRNA-4454 As Mediators of Facet Cartilage Degeneration

Biology and Pathology of Bone and Joint - Poster I

9:00AM-11:00AM: Abstract Number: 2142

Identification of Novel Molecules Targeting Cartilage Aging As Osteoarthritis Therapeutics

Biology and Pathology of Bone and Joint - Poster I

9:00AM-11:00AM: Abstract Number: 2817

Identification of Subsets of Systemic Lupus Erythematosus Patients By Principal Component Analysis and Urine Biomarkers

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2967

Identifying Core Domains for BehçEt’s Syndrome Trials: An International Physician and Patient Delphi Exercise

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2864

Identifying Dysregulated and Co-Dysregulated Markers in Systemic Lupus Erythematosus Using Multi-Modal Biomarker Data from a Large Pre-Clinical Study

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2461

Identifying Flare in Rheumatoid Arthritis: What Is the Threshold?

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2475

Identifying Key Variables for Inclusion in a Smartphone App to Support Clinical Care and Research in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2574

IL-22 As a Biomarker for Erosive Disease in Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III

9:00AM-11:00AM: Abstract Number: 2156

IL-6 and TNF-α Modulate Expressions of Cell Cycle Regulators of Rheumatoid Arthritis Fibroblast-like Synoviocytes

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2731

Illness Perceptions and Health-Related Quality of Life in Patients with Axial Spondyloarthritis and Other Forms of Chronic Back Pain in the Spondyloarthritis Caught Early (SPACE)-Cohort

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2432

Immune Abnormalities Leading to Exaggerated Production of IFN-Gamma (IFNγ) and the Therapeutic Response to an Anti-IFNγ Antibody in a Patient with NRLC4 Mediated Disease

Pediatric Rheumatology – Pathogenesis and Genetics - Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].